Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Disease Sites:

Lung

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Ceralasertib, Durvalumab

Principal Investigator(s):

Gibson, Mike

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

12-17-2025

Trial Type:

Treatment

Protocol ID:

ECOGTHOEA5231

National Clinical Trial ID:

NCT06732401

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

ALL

Accepts Healthy Volunteers?:

false

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Eligibility